{
    "id": 28875,
    "fullName": "EGFR - FGFR1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR-FGFR1 results from the fusion of EGFR and FGFR1 (PMID: 29883838). EGFR-FGFR1 has been identified in non-small cell lung cancer (PMID: 29883838), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "EGFR - FGFR1",
    "createDate": "10/25/2018",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2260,
                "geneSymbol": "FGFR1",
                "terms": [
                    "FGFR1",
                    "bFGF-R-1",
                    "BFGFR",
                    "CD331",
                    "CEK",
                    "ECCL",
                    "FGFBR",
                    "FGFR-1",
                    "FLG",
                    "FLT-2",
                    "FLT2",
                    "HBGFR",
                    "HH2",
                    "HRTFDS",
                    "KAL2",
                    "N-SAM",
                    "OGD"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15136,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib) followed by Tagrisso (osimertinib), EGFR L858R and EGFR-FGFR1 were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30784,
                "profileName": "EGFR - FGFR1 EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30783,
            "profileName": "EGFR - FGFR1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30784,
            "profileName": "EGFR - FGFR1 EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}